STOCK TITAN

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Stoke Therapeutics (Nasdaq: STOK), a biotechnology firm focused on RNA-based medicines, will present at two major investor conferences in June 2024. The events include the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 at 4:00 p.m. ET and the TD Cowen Genetic Medicines & RNA Summit on June 20 at 10:00 a.m. ET. Live webcasts and replays of these events will be accessible on the company's investor relations website.

Positive
  • Stoke Therapeutics is gaining visibility by presenting at high-profile investor conferences.
  • Participation in major events like the Goldman Sachs and TD Cowen conferences can attract potential investors and partners.
  • Providing live webcasts and replays increases transparency and accessibility for stakeholders.
Negative
  • No new data or significant milestones were announced in the PR, which might not create immediate investor excitement.
  • The PR does not address any financial updates or clinical trial progress, potentially leaving investors wanting more substantive information.

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences:

Goldman Sachs 45th Annual Global Healthcare Conference
Date: Monday, June 10, 2024
Time: 4:00 p.m. ET

TD Cowen Genetic Medicines & RNA Summit
Date: Thursday, June 20, 2024
Time: 10:00 a.m. ET

Live webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

Stoke Investor Contact:

Eric Rojas

Vice President, Investor Relations

IR@stoketherapeutics.com

617-312-2754

Source: Stoke Therapeutics, Inc.

FAQ

What events will Stoke Therapeutics (STOK) participate in June 2024?

Stoke Therapeutics will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 and the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024.

When and where is the Goldman Sachs 45th Annual Global Healthcare Conference?

The Goldman Sachs 45th Annual Global Healthcare Conference will take place on June 10, 2024, at 4:00 p.m. ET.

When is the TD Cowen Genetic Medicines & RNA Summit?

The TD Cowen Genetic Medicines & RNA Summit is scheduled for June 20, 2024, at 10:00 a.m. ET.

How can I access the webcasts of Stoke Therapeutics' presentations?

Live webcasts and replays of Stoke Therapeutics' presentations will be available on the company's investor relations website.

Stoke Therapeutics, Inc.

NASDAQ:STOK

STOK Rankings

STOK Latest News

STOK Stock Data

742.72M
52.12M
4.57%
98.09%
16.04%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BEDFORD